Lung Cancer Clinical Trial
Official title:
A Pilot Study of FOLFOX in Combination With Bevacizumab in Patients With Advanced Neuroendocrine Tumors
Verified date | December 2019 |
Source | University of California, San Francisco |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of neuroendocrine tumors by blocking blood flow to the tumor. Giving combination chemotherapy together with bevacizumab may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects of giving combination chemotherapy together with bevacizumab and to see how well it works in treating patients with advanced neuroendocrine tumors.
Status | Terminated |
Enrollment | 36 |
Est. completion date | February 2016 |
Est. primary completion date | January 2012 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed neuroendocrine tumor (NET) - Carcinoid at any site, with or without carcinoid syndrome - Pancreatic islet cell tumor - Prior streptozocin-based therapy not required - Poorly differentiated NET of any primary site (this arm closed to accrual May 2009) - Progression with prior treatment with cisplatin-, or carboplatin-based chemotherapy required (unless contraindicated) - The following tumors are not allowed: - Endocrine organ carcinoma - Adrenal gland malignancies - Thyroid carcinoma of any histology - Pheochromocytoma/paraganglioma - Advanced disease - Disease not amenable to surgery, radiotherapy, or combined modality therapy with curative intent - Radiologically or clinically confirmed progressive disease - At least 25% increase in radiologically or clinically measurable disease - At least 20% increase in the longest diameter (LD) of any previously documented lesion - Increase in the sum of the LD of multiple lesions in aggregate of 20%, OR appearance of new lesions OR deterioration in clinical status - Measurable disease - At least 1 unidimensionally measurable lesion = 20 mm by conventional radiographic techniques OR = 10 mm by spiral CT scan - Ultrasound or positron-emission tomography alone not sufficient - Bone lesions, ascites, peritoneal carcinomatosis, pleural or pericardial effusion, and irradiated lesions are not considered measurable disease - Primary tumors of the pancreas should not invade adjacent organs (e.g., stomach or duodenum) - No history or evidence of brain or leptomeningeal disease (baseline CNS imaging required if clinical suspicion of CNS metastases) PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-1 Life expectancy - More than 12 weeks Hematopoietic - Absolute neutrophil count = 1,500/mm^3 - Platelet count = 100,000/mm^3 - No history of hemoptysis or bleeding diathesis - No coagulopathy unrelated to therapeutic anticoagulation - No significant bleeding events within the past 6 months unless the source of the bleeding has been resected Hepatic - Bilirubin < 2 mg/dL - ALT = 2.5 times upper limit of normal (ULN) (5 times ULN if due to liver metastases) Renal - Creatinine = 2 mg/dL - Protein = 1+ OR - Protein < 1 gm on 24-hour urine collection - Urine protein:creatinine ratio < 1.0 Cardiovascular - History of thromboembolic condition allowed provided patient is on therapeutic anticoagulation at a stable dose for = 4 weeks - Concurrent daily prophylactic aspirin (< 325 mg/day) allowed - No uncontrolled hypertension, myocardial infarction, clinically significant peripheral arterial ischemia, visceral arterial ischemia or angina within the past 6 months - No serious cardiac arrhythmia requiring medication - No cerebrovascular event (e.g., stroke or transient ischemic attack) within the past 12 months - No history of peripheral vascular disease = grade 2 - No history New York Heart Association class II-IV congestive heart failure - Blood pressure = 160/90 mm Hg Gastrointestinal - No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months - No predisposing uncontrolled small bowel or colonic disorder - Baseline disease-related diarrhea allowed if symptoms are stable and well-characterized (i.e., # stools/day stable) - No gastric or esophageal varices - No gastroduodenal ulcers determined to be active by endoscopy Pulmonary - No interstitial pneumonia or extensive and symptomatic interstitial fibrosis - No lung tumor in close proximity to a major vessel, or with associated cavitation - No pleural effusion or ascites that causes = grade 2 dyspnea Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for at least 3 months after completion of study treatment - No significant traumatic injury within the past 28 days - No currently active second malignancy other than, non-melanoma skin cancer or carcinoma in situ - Patients are not considered to have a currently active malignancy if they have completed therapy and are considered by their physician to be at = 30% risk for relapse - No known hypersensitivity reaction attributed to study drugs or to compounds of similar chemical or biological composition - No symptomatic peripheral neuropathy > grade 1 - No other severe disease or comorbidity that would preclude study participation - No medically uncontrolled seizures - No active infection - No serious non-healing wound, ulcer, or bone fracture - No psychiatric illness or social situation that would preclude study compliance - No other severe, concurrent disease, infection, or co-morbidity that in the judgement of the investigator would constitute a hazard for study participation PRIOR CONCURRENT THERAPY: Biologic therapy - Recovered from prior cytokine therapy - At least 4 weeks since prior immunotherapy - No prior tyrosine kinase inhibitors or anti-vascular endothelial growth factor (VEGF) angiogenic inhibitors Chemotherapy - See Disease Characteristics - At least 4 weeks since prior chemotherapy - No prior oxaliplatin - Prior chemoembolization therapy allowed provided it did not affect areas of measurable disease Endocrine therapy - Prior and concurrent somatostatin analogs allowed for symptomatic control and/or control of hormone hypersecretion only provided treatment was initiated > 3 months prior to study entry Radiotherapy - See Disease Characteristics - At least 4 weeks since prior radiotherapy and recovered - Prior radiotherapy must not affect areas of measurable disease - No concurrent radiotherapy to only site of measurable disease Surgery - Recovered from prior surgery - Prior cryotherapy allowed provided it did not affect areas of measurable disease - At least 28 days since prior major surgical procedure or open biopsy - At least 7 days since minor surgical procedure, fine-needle aspirations, or core biopsy - No prior organ allograft - No concurrent major surgery Other - At least 4 weeks since prior participation in an experimental drug study - No other concurrent investigational agents - No other concurrent anticancer therapy - No halogenated antiviral agents - Concurrent antiplatelet agents allowed |
Country | Name | City | State |
---|---|---|---|
United States | Univeristy of California, San Francisco | San Francisco | California |
United States | Kaiser Permanente Medical Center - Vallejo | Vallejo | California |
Lead Sponsor | Collaborator |
---|---|
University of California, San Francisco | Genentech, Inc., Sanofi |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of Discontinuation Due to Adverse Events Possibly Related to Study Treatment | Rates of discontinuation were calculated as counts and percentages of patients whom discontinued treatment due to adverse events possibly related to the investigational treatments not including neuropathy. | From beginning of treatment up to 18 months; Post-study survival follow-up up to 8 years | |
Primary | Best Objective Response | Best Objective Response by RECIST with Exact 95% Binomial CIs across all tumor types. The patient's best response assignment will depend on the achievement of both measurement and confirmation criteria Target lesions response + Non-Target lesions response + Evaluation of non-target lesions (Yes / No) = Overall response | From Baseline until disease progression, up to 8 years | |
Secondary | Time to Progression | Time to disease progression will be defined as the time from baseline until documented disease progression or death (whichever occurs first). | From beginning of treatment up to 18 months; Post-study survival follow-up up to 8 years | |
Secondary | Overall Median Survival | The overall survival is defined as the time from baseline until death (Carcinoid, PNET, PDNEC) using Kaplan-Meier Survival analysis methods. | until death, up to 8 years | |
Secondary | Overall Time to Treatment Failure | Time to treatment failure is defined as the time from the initial complete or partial response to documented disease progression or death (whichever occurs first) across treatment groups and inclusive of drug holidays and estimated using Kaplan-Meier survival analysis methods | From initial complete or partial response to disease progression, up to 8 years | |
Secondary | Biochemical Marker Response | Biochemical marker response is defined as >=50% reduction in marker or hormone(s) that were elevated at baseline. Markers/hormones tested are: Chromagranin A (CGA), 5-HIAA, Insulin, Proinsulin, C-peptide, Pancreatic polypeptide, Gastrin, Glucagon, and Vasointestinal Peptide. | From Baseline until end of treatment, up to 8 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|